Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin + Chemotherapy in Advanced ESCC
NCT03833466Phase 2Unknown
- Sponsor
- Peking University
- Start
- Feb 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liquid metformin (Aspargo Labs) in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University. Primary endpoints: Tumor metabolic pathway at 1 year and Tumor microenvironment at 1 year. Status: unknown.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03833466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03833466.